A Theoretical Analysis of the Prodrug Delivery System for Treating Antibiotic-Resistant Bacteria

Simulations were carried out to analyze a promising new antimicrobial treatment strategy for targeting antibiotic-resistant bacteria called the \beta-lactamase-dependent prodrug delivery system. In this system, the antibacterial drugs are delivered as inactive precursors that only become activated after contact with an enzyme characteristic of many species of antibiotic-resistant bacteria (\beta-lactamase enzyme). The addition of an activation step contributes an extra layer of complexity to the system that can lead to unexpected emergent behavior. In order to optimize for treatment success and minimize the risk of resistance development, there must be a clear understanding of the system dynamics taking place and how they impact on the overall response. It makes sense to use a systems biology approach to analyze this method because it can facilitate a better understanding of the complex emergent dynamics arising from diverse interactions in populations. This paper contains an initial theoretical examination of the dynamics of this system of activation and an assessment of its therapeutic potential from a theoretical standpoint using an agent-based modeling approach. It also contains a case study comparison with real-world results from an experimental study carried out on two prodrug candidate compounds in the literature.

[1]  E. Allman,et al.  Identifiability of Two-Tree Mixtures for Group-Based Models , 2011, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[2]  M. Devocelle,et al.  Modeling the Population Dynamics of Antibiotic-Resistant Bacteria:. AN Agent-Based Approach , 2009 .

[3]  M. Devocelle,et al.  A computational model of antibiotic-resistance mechanisms in methicillin-resistant Staphylococcus aureus (MRSA). , 2008, Journal of theoretical biology.

[4]  Tycho Heimbach,et al.  Prodrugs: design and clinical applications , 2008, Nature Reviews Drug Discovery.

[5]  Roberta B Carey,et al.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.

[6]  Alan Forrest,et al.  Erratum: Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore (Clinical Infectious Diseases (2007) 44, (79-86)) , 2007 .

[7]  R. Gaynes,et al.  Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  A. D. Russell,et al.  Triclosan–bacteria interactions: single or multiple target sites? , 2005, Letters in applied microbiology.

[9]  S. Mobashery,et al.  β-Lactam resistance in Staphylococcus aureus: the adaptive resistance of a plastic genome , 2005, Cellular and Molecular Life Sciences.

[10]  Samy O Meroueh,et al.  Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. , 2005, Chemical reviews.

[11]  S. Levy,et al.  Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.

[12]  K. Bush,et al.  Taking inventory: antibacterial agents currently at or beyond phase 1. , 2004, Current opinion in microbiology.

[13]  N. Georgopapadakou,et al.  Mechanism of Action of NB2001 and NB2030, Novel Antibacterial Agents Activated by β-Lactamases , 2004, Antimicrobial Agents and Chemotherapy.

[14]  D. Andersson,et al.  Persistence of antibiotic resistant bacteria. , 2003, Current opinion in microbiology.

[15]  F. Lowy Antimicrobial resistance: the example of Staphylococcus aureus. , 2003, The Journal of clinical investigation.

[16]  G. Wahl,et al.  NB2001, a Novel Antibacterial Agent with Broad-Spectrum Activity and Enhanced Potency against β-Lactamase-Producing Strains , 2002, Antimicrobial Agents and Chemotherapy.

[17]  Marta Ginovart,et al.  INDISIM, an individual-based discrete simulation model to study bacterial cultures. , 2002, Journal of theoretical biology.

[18]  M. Kuroda,et al.  The emergence and evolution of methicillin-resistant Staphylococcus aureus. , 2001, Trends in microbiology.

[19]  D. D. Jaworski,et al.  Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus. , 2001, The Journal of antimicrobial chemotherapy.

[20]  T. Smyth,et al.  β-Lactamase-Dependent Prodrugs—Recent Developments , 2000 .

[21]  J. Newman,et al.  Triclosan: a review of effectiveness and safety in health care settings. , 2000, American journal of infection control.

[22]  R. Lewis,et al.  Proteolytic cleavage of the repressor (BlaI) of beta-lactamase synthesis in Staphylococcus aureus. , 1999, FEMS microbiology letters.

[23]  P. Giesbrecht,et al.  Staphylococcal Cell Wall: Morphogenesis and Fatal Variations in the Presence of Penicillin , 1998, Microbiology and Molecular Biology Reviews.

[24]  L. Kotra,et al.  β-Lactam antibiotics, β-lactamases and bacterial resistance , 1998 .

[25]  D. Kernodle,et al.  Production of A and C variants of staphylococcal beta-lactamase by methicillin-resistant strains of Staphylococcus aureus , 1994, Antimicrobial Agents and Chemotherapy.

[26]  N. G. Heatley,et al.  Penicillin as a chemotherapeutic agent. 1940. , 1993, Clinical orthopaedics and related research.

[27]  H. Neu,et al.  The Crisis in Antibiotic Resistance , 1992, Science.

[28]  G. Forbes Penicillin-resistant Staphylococci , 1949 .

[29]  G. Hobby,et al.  PENICILLIN AS A CHEMOTHERAPEUTIC AGENT , 1943 .

[30]  Alan Forrest,et al.  Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  Nicholas R. Jennings,et al.  A Roadmap of Agent Research and Development , 2004, Autonomous Agents and Multi-Agent Systems.

[32]  N. Georgopapadakou,et al.  Mechanism of Action of NB2001 and NB2030, Novel Antibacterial Agents Activated by (cid:2) -Lactamases , 2004 .